Based on our research and experience, market access strategy and execution is one of the primary contributors to enabling product launch success. The ever-increasing costs of drug development, intense competition, payer controls, and complex distribution logistics often make it challenging for life sciences companies to deliver on their launch ambition. It is important to have a robust market access launch strategy that considers a product’s specific therapeutic archetype. Join Deloitte and market access leaders as they explore:
Sandeep Duttagupta, PhD is currently the Vice President of Global Pricing & Market Access (P&MA) at Alnylam. In this role Sandeep’s responsibilities include overseeing Alnylam’s P&MA strategies/execution for its entire portfolio, managing the global governance around P&MA, and working closely with Regional Access teams to maximize the value of our programs, and playing a key role in developing future innovative access programs per Alnylam’s Patient Access philosophy. Sandeep Duttagupta, PhD is currently the Vice President of Global Pricing & Market Access (P&MA) at Alnylam. In this role Sandeep’s responsibilities include overseeing Alnylam’s P&MA strategies/execution for its entire portfolio, managing the global governance around P&MA, and working closely with Regional Access teams to maximize the value of our programs, and playing a key role in developing future innovative access programs per Alnylam’s Patient Access philosophy.
Sandeep brings over 25 years of global industry and management consulting experience, specializing in global pricing and market access for biopharmaceutical products. Most recently he was a Partner at DRG/Clarivate Consulting and Practice Lead for Global Pricing and Market Access. He joined erstwhile-DRG Consulting in 2018 and advised biopharmaceutical clients in their go-to-market pricing and patient access strategies across US, Europe, Japan, China and Emerging Markets. He worked with both government and private healthcare payers across the globe to help key pharma and biotech clients maximize access to patients for innovative medicines.
Prior to DRG/Clarivate, Sandeep was at CBPartners, a NYC-based boutique life sciences strategy consulting firm specializing in value, access and pricing, where he held the role of Senior Vice President, Business Development. During his tenure, he helped expand the firm’s business into a substantial number of new clients across various geographies. Prior to this, Sandeep spent 17 years at Pfizer, across positions of increasing responsibility, first within Global and US HEOR, and then for 10 years in various Global Pricing and Market Access functions. His last position was as the Vice President of P&MA for Pfizer’s Emerging Market Business Unit, where he had the opportunity to reshape internal thinking and business models in low-to-middle-income countries across Pfizer’s portfolio. Additionally, on behalf of PhRMA, he was often the face of the pharmaceutical industry in shaping industry-friendly government policies in a large number of countries.
Sandeep also serves as an Executive Board member for privately held Aquavit Pharmaceuticals and Celanese (NYSE: CE).
Brian brings 20 years of experience in the area of biopharmaceutical value and access. He has dedicated his career to advancing new perspectives on the growing challenge of sustainable affordability, access, and value across traditional and increasingly transformative drug therapies in cell & gene therapy and rare diseases. In his career he delivered value and access strategy for 250+ therapies, and has supported most of the leading life sciences companies, advised payer and provider clients, and advanced government policy initiatives in the US and Globally.
Brian has multiple leadership capacities within Deloitte, including, but not limited to: